Review



prmt1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc prmt1
    Prmt1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 185 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/Asymmetric+Di-Methyl+Arginine+Motif+%5Badme-R%5D+MultiMab+Rabbit+mAb+mix/pm41912914-70-6-8
    Average 96 stars, based on 185 article reviews
    prmt1 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    Cell Characterization:

    Article Title: Exercise preconditioning prevents immobilization-induced skeletal muscle atrophy by activating Prmt1-p38/ATF2-Sesn1 signaling axis in C57BL/6J mice
    Article Snippet: .. The antibodies are listed below: aDMA (Anti-Asymmetric Di-Methyl Arginine Motif) (1:1 500, Rabbit, Cell Signal Tech, USA), Akt (protein kinase B) (1:2 000, Mouse, Proteintech, USA), pAkt-Ser473 (1:2 000, Rabbit, Cell Signal Tech, USA), AMPKα2 (1:2 000, Rabbit, Cell Signal Tech, USA), pAMPK-Thr172 (1:2 000, Rabbit, Cell Signal Tech, USA), ATF2 (1:2 000, Rabbit, Proteintech, USA), Atrogin-1 (FBXO32) (1:15 000, Mouse, Proteintech, USA), FoxO3a (Forkhead box O3) (1:1 000, Mouse, Proteintech, USA), pFoxO3a-Ser315 (1:2 000, Rabbit, Proteintech, USA), GAPDH (1:5 000, Rabbit, Utibody, CN), IGF-1 (insulin-like growth factor 1) (1:2 000, Mouse, Proteintech, USA), LaminB (1:2 000, Rabbit, Abcam, USA), MEF2 (myocyte enhancer factor 2) (1:2 000, Rabbit, Proteintech, USA), Myf5 (myogenic factor 5) (1:2 000, Rabbit, Abclonal, CN), MyoD (myogenic differentiation antigen) (1:2 000, Rabbit, Proteintech, USA), MyoG (myogenin) (1:2 000, Rabbit, Proteintech, USA). mTOR (mammalian target of rapamycin) (1:2 000, Rabbit, Cell Signal Tech, USA), p38 (1:2 000, Rabbit, WANLEIBIO, CN), p-p38-Thr180/Tyr182 (1:2 000, Rabbit, WANLEIBIO, CN), PGC-1α (1:1 000, Rabbit, Abcam, USA), Prmt1 (1:2 000, Rabbit, Cell Signal Tech, USA), Raptor (1:1 000, Rabbit, Cell Signal Tech, USA), Sesn1 (1:1 000, Rabbit, HUABIO, CN), Sesn1 (1:1 000, Rabbit, Abcam, USA), TRIM63 (MuRF1) (1:2 000, Rabbit, Proteintech, USA). ..

    Pyrolysis Gas Chromatography:

    Article Title: Exercise preconditioning prevents immobilization-induced skeletal muscle atrophy by activating Prmt1-p38/ATF2-Sesn1 signaling axis in C57BL/6J mice
    Article Snippet: .. The antibodies are listed below: aDMA (Anti-Asymmetric Di-Methyl Arginine Motif) (1:1 500, Rabbit, Cell Signal Tech, USA), Akt (protein kinase B) (1:2 000, Mouse, Proteintech, USA), pAkt-Ser473 (1:2 000, Rabbit, Cell Signal Tech, USA), AMPKα2 (1:2 000, Rabbit, Cell Signal Tech, USA), pAMPK-Thr172 (1:2 000, Rabbit, Cell Signal Tech, USA), ATF2 (1:2 000, Rabbit, Proteintech, USA), Atrogin-1 (FBXO32) (1:15 000, Mouse, Proteintech, USA), FoxO3a (Forkhead box O3) (1:1 000, Mouse, Proteintech, USA), pFoxO3a-Ser315 (1:2 000, Rabbit, Proteintech, USA), GAPDH (1:5 000, Rabbit, Utibody, CN), IGF-1 (insulin-like growth factor 1) (1:2 000, Mouse, Proteintech, USA), LaminB (1:2 000, Rabbit, Abcam, USA), MEF2 (myocyte enhancer factor 2) (1:2 000, Rabbit, Proteintech, USA), Myf5 (myogenic factor 5) (1:2 000, Rabbit, Abclonal, CN), MyoD (myogenic differentiation antigen) (1:2 000, Rabbit, Proteintech, USA), MyoG (myogenin) (1:2 000, Rabbit, Proteintech, USA). mTOR (mammalian target of rapamycin) (1:2 000, Rabbit, Cell Signal Tech, USA), p38 (1:2 000, Rabbit, WANLEIBIO, CN), p-p38-Thr180/Tyr182 (1:2 000, Rabbit, WANLEIBIO, CN), PGC-1α (1:1 000, Rabbit, Abcam, USA), Prmt1 (1:2 000, Rabbit, Cell Signal Tech, USA), Raptor (1:1 000, Rabbit, Cell Signal Tech, USA), Sesn1 (1:1 000, Rabbit, HUABIO, CN), Sesn1 (1:1 000, Rabbit, Abcam, USA), TRIM63 (MuRF1) (1:2 000, Rabbit, Proteintech, USA). ..

    Western Blot:

    Article Title: Targeting TRIM59 impairs RNA splicing and promotes neuroblastoma differentiation and therapeutic responses.
    Article Snippet: All cell lines were recently authenticated using STR DNA fingerprinting at Shanghai Biowing Applied Biotechnology Co., Ltd (Shanghai, China), and mycoplasma infection was detected using LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich). .. The following primary antibodies were used in this study: GAPDH (1:1000 for WB, 10494-1-AP, Proteintech), TRIM59 (1:500 for WB, 1:500 for IF, 1:1200 for IHC, ab69639, Abcam), SFPQ (1:2000 for WB, 1:200 for IF, SAB4200501, Sigma), SOX2 (1:1000 for WB, ab92494, Abcam), TUJ1 (1:1000 for WB, 1:1000 for IF, 801213, Biolegend), MYCN (1:1000, 84406, Cell Signaling Technology), Ki67 (1:500, 9449, Cell Signaling Technology), MAP2 (1:250 for IHC, 4542, Cell Signaling Technology), Lamin B1 (1:5000, 66095-1-Ig, Proteintech), PIN1 (1:1000 for WB, sc-46660, Santa Cruz), pan-Asymmetric-Di-Methyl Arginine (1:1000 for WB, M005375, Abmart), HA-Tag (1:5000 for WB, 51064-2-AP, AR TIC LE IN PR ES S 9 Proteintech), PRMT1 (1:1000 for WB, 2449, CST), Flag-Tag (1:3000 for WB, 66008-4-Ig, Proteintech), Myc-Tag (1:1000 for WB, M20002, Abmart), NDRG1 (1:1000 for WB, 26902-4-Ig, Proteintech). ..

    Article Title: Targeting TRIM59 impairs RNA splicing and promotes neuroblastoma differentiation and therapeutic responses
    Article Snippet: All cell lines were recently authenticated using STR DNA fingerprinting at Shanghai Biowing Applied Biotechnology Co., Ltd (Shanghai, China), and mycoplasma infection was detected using LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich). .. The following primary antibodies were used in this study: GAPDH (1:1000 for WB, 10494-1-AP, Proteintech), TRIM59 (1:500 for WB, 1:500 for IF, 1:1200 for IHC, ab69639, Abcam), SFPQ (1:2000 for WB, 1:200 for IF, SAB4200501, Sigma), SOX2 (1:1000 for WB, ab92494, Abcam), TUJ1 (1:1000 for WB, 1:1000 for IF, 801213, Biolegend), MYCN (1:1000, 84406, Cell Signaling Technology), Ki67 (1:500, 9449, Cell Signaling Technology), MAP2 (1:250 for IHC, 4542, Cell Signaling Technology), Lamin B1 (1:5000, 66095-1-Ig, Proteintech), PIN1 (1:1000 for WB, sc-46660, Santa Cruz), pan-Asymmetric-Di-Methyl Arginine (1:1000 for WB, M005375, Abmart), HA-Tag (1:5000 for WB, 51064-2-AP, Proteintech), PRMT1 (1:1000 for WB, 2449, CST), Flag-Tag (1:3000 for WB, 66008-4-Ig, Proteintech), Myc-Tag (1:1000 for WB, M20002 , Abmart), NDRG1 (1:1000 for WB, 26902-4-Ig, Proteintech). ..

    Immunohistochemistry:

    Article Title: Targeting TRIM59 impairs RNA splicing and promotes neuroblastoma differentiation and therapeutic responses.
    Article Snippet: All cell lines were recently authenticated using STR DNA fingerprinting at Shanghai Biowing Applied Biotechnology Co., Ltd (Shanghai, China), and mycoplasma infection was detected using LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich). .. The following primary antibodies were used in this study: GAPDH (1:1000 for WB, 10494-1-AP, Proteintech), TRIM59 (1:500 for WB, 1:500 for IF, 1:1200 for IHC, ab69639, Abcam), SFPQ (1:2000 for WB, 1:200 for IF, SAB4200501, Sigma), SOX2 (1:1000 for WB, ab92494, Abcam), TUJ1 (1:1000 for WB, 1:1000 for IF, 801213, Biolegend), MYCN (1:1000, 84406, Cell Signaling Technology), Ki67 (1:500, 9449, Cell Signaling Technology), MAP2 (1:250 for IHC, 4542, Cell Signaling Technology), Lamin B1 (1:5000, 66095-1-Ig, Proteintech), PIN1 (1:1000 for WB, sc-46660, Santa Cruz), pan-Asymmetric-Di-Methyl Arginine (1:1000 for WB, M005375, Abmart), HA-Tag (1:5000 for WB, 51064-2-AP, AR TIC LE IN PR ES S 9 Proteintech), PRMT1 (1:1000 for WB, 2449, CST), Flag-Tag (1:3000 for WB, 66008-4-Ig, Proteintech), Myc-Tag (1:1000 for WB, M20002, Abmart), NDRG1 (1:1000 for WB, 26902-4-Ig, Proteintech). ..

    Article Title: Targeting TRIM59 impairs RNA splicing and promotes neuroblastoma differentiation and therapeutic responses
    Article Snippet: All cell lines were recently authenticated using STR DNA fingerprinting at Shanghai Biowing Applied Biotechnology Co., Ltd (Shanghai, China), and mycoplasma infection was detected using LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich). .. The following primary antibodies were used in this study: GAPDH (1:1000 for WB, 10494-1-AP, Proteintech), TRIM59 (1:500 for WB, 1:500 for IF, 1:1200 for IHC, ab69639, Abcam), SFPQ (1:2000 for WB, 1:200 for IF, SAB4200501, Sigma), SOX2 (1:1000 for WB, ab92494, Abcam), TUJ1 (1:1000 for WB, 1:1000 for IF, 801213, Biolegend), MYCN (1:1000, 84406, Cell Signaling Technology), Ki67 (1:500, 9449, Cell Signaling Technology), MAP2 (1:250 for IHC, 4542, Cell Signaling Technology), Lamin B1 (1:5000, 66095-1-Ig, Proteintech), PIN1 (1:1000 for WB, sc-46660, Santa Cruz), pan-Asymmetric-Di-Methyl Arginine (1:1000 for WB, M005375, Abmart), HA-Tag (1:5000 for WB, 51064-2-AP, Proteintech), PRMT1 (1:1000 for WB, 2449, CST), Flag-Tag (1:3000 for WB, 66008-4-Ig, Proteintech), Myc-Tag (1:1000 for WB, M20002 , Abmart), NDRG1 (1:1000 for WB, 26902-4-Ig, Proteintech). ..



    Similar Products

    94
    ABclonal Biotechnology prmt1
    Prmt1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/PRMT1+Rabbit+pAb/pm42660379-106-33-36
    Average 94 stars, based on 1 article reviews
    prmt1 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    98
    Cytiva Europe histrap ff
    Histrap Ff, supplied by Cytiva Europe, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/HisTrap+FF/custom%4017525501%4041704006
    Average 98 stars, based on 1 article reviews
    histrap ff - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc prmt1
    Prmt1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/Asymmetric+Di-Methyl+Arginine+Motif+%5Badme-R%5D+MultiMab+Rabbit+mAb+mix/pm41912914-70-6-8
    Average 96 stars, based on 1 article reviews
    prmt1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    86
    Misuzu Corporation Co Ltd prmt1
    Protein arginine methylation from biochemical discovery to therapeutic targeting. A , Timeline of key advances in arginine methylation biology, highlighting the progression from early biochemical identification of methylarginine and methyltransferase activity ( <xref ref-type=15 , 16 , 17 ) to molecular definition of protein arginine methyltransferases (PRMTs) ( 18 , 19 ). Early mechanistic studies demonstrated that arginine methylation regulates protein–protein interactions ( 20 ) and chromatin function through histone methylation by CARM1/PRMT4, PRMT1, and PRMT5 ( 21 , 22 , 23 ), while PRMT7 is unique in only catalyzing monomethylation ( 24 , 25 ). Tool development of specific antibodies ( 26 , 27 ) and inhibitors helped advance the field. The identification of methylarginine reader proteins, including SMN and TDRD3, and the structural definition of Tudor domain recognition established principles of methylarginine-dependent signaling ( 28 , 29 , 30 , 31 , 32 , 33 ). Translational advances include the development of selective PRMT5 inhibitors ( 34 , 35 ) and the discovery that MTAP loss leads to accumulation of methylthioadenosine (MTA), creating a synthetic lethal vulnerability to PRMT5 inhibition ( 36 , 37 , 38 ). More recent discoveries expanded methylarginine reader biology beyond Tudor domains, including SART3 ( 39 ) and established MTA-cooperative PRMT5 inhibitors that exploit tumor metabolic state for selective targeting ( 40 , 41 ). Colored boxes denote conceptual categories: enzyme discovery, biochemistry, and biology (green); methylarginine readers and mechanisms (purple); and therapeutic development (orange). B , Biochemical reactions catalyzed by PRMTs. Type I, II, and III PRMTs catalyze processive methylation of arginine residues using S-adenosylmethionine (SAM) as a methyl donor, generating monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), or symmetric dimethylarginine (SDMA/Rme2s), with S-adenosylhomocysteine (SAH) as a byproduct. PRMT family members are classified by product specificity: Type I catalyzing MMA and ADMA (PRMT1, 2, 3, 4, 6, and 8), Type II catalyzing MMA and SDMA (PRMT5 and 9), and Type III only catalyzing MMA (PRMT7). " width="250" height="auto" />
    Prmt1, supplied by Misuzu Corporation Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/pmc13208669-62-15-2
    Average 86 stars, based on 1 article reviews
    prmt1 - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    94
    BPS Bioscience prmt1
    Protein arginine methylation from biochemical discovery to therapeutic targeting. A , Timeline of key advances in arginine methylation biology, highlighting the progression from early biochemical identification of methylarginine and methyltransferase activity ( <xref ref-type=15 , 16 , 17 ) to molecular definition of protein arginine methyltransferases (PRMTs) ( 18 , 19 ). Early mechanistic studies demonstrated that arginine methylation regulates protein–protein interactions ( 20 ) and chromatin function through histone methylation by CARM1/PRMT4, PRMT1, and PRMT5 ( 21 , 22 , 23 ), while PRMT7 is unique in only catalyzing monomethylation ( 24 , 25 ). Tool development of specific antibodies ( 26 , 27 ) and inhibitors helped advance the field. The identification of methylarginine reader proteins, including SMN and TDRD3, and the structural definition of Tudor domain recognition established principles of methylarginine-dependent signaling ( 28 , 29 , 30 , 31 , 32 , 33 ). Translational advances include the development of selective PRMT5 inhibitors ( 34 , 35 ) and the discovery that MTAP loss leads to accumulation of methylthioadenosine (MTA), creating a synthetic lethal vulnerability to PRMT5 inhibition ( 36 , 37 , 38 ). More recent discoveries expanded methylarginine reader biology beyond Tudor domains, including SART3 ( 39 ) and established MTA-cooperative PRMT5 inhibitors that exploit tumor metabolic state for selective targeting ( 40 , 41 ). Colored boxes denote conceptual categories: enzyme discovery, biochemistry, and biology (green); methylarginine readers and mechanisms (purple); and therapeutic development (orange). B , Biochemical reactions catalyzed by PRMTs. Type I, II, and III PRMTs catalyze processive methylation of arginine residues using S-adenosylmethionine (SAM) as a methyl donor, generating monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), or symmetric dimethylarginine (SDMA/Rme2s), with S-adenosylhomocysteine (SAH) as a byproduct. PRMT family members are classified by product specificity: Type I catalyzing MMA and ADMA (PRMT1, 2, 3, 4, 6, and 8), Type II catalyzing MMA and SDMA (PRMT5 and 9), and Type III only catalyzing MMA (PRMT7). " width="250" height="auto" />
    Prmt1, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/PRMT1%2C+GST-tag+(E%2E+coli-derived)+Recombinant/10__1158_slash_1535___7163__mct___25___1105-43-5-14
    Average 94 stars, based on 1 article reviews
    prmt1 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    OriGene fulllength recombinant human prmt1
    Protein arginine methylation from biochemical discovery to therapeutic targeting. A , Timeline of key advances in arginine methylation biology, highlighting the progression from early biochemical identification of methylarginine and methyltransferase activity ( <xref ref-type=15 , 16 , 17 ) to molecular definition of protein arginine methyltransferases (PRMTs) ( 18 , 19 ). Early mechanistic studies demonstrated that arginine methylation regulates protein–protein interactions ( 20 ) and chromatin function through histone methylation by CARM1/PRMT4, PRMT1, and PRMT5 ( 21 , 22 , 23 ), while PRMT7 is unique in only catalyzing monomethylation ( 24 , 25 ). Tool development of specific antibodies ( 26 , 27 ) and inhibitors helped advance the field. The identification of methylarginine reader proteins, including SMN and TDRD3, and the structural definition of Tudor domain recognition established principles of methylarginine-dependent signaling ( 28 , 29 , 30 , 31 , 32 , 33 ). Translational advances include the development of selective PRMT5 inhibitors ( 34 , 35 ) and the discovery that MTAP loss leads to accumulation of methylthioadenosine (MTA), creating a synthetic lethal vulnerability to PRMT5 inhibition ( 36 , 37 , 38 ). More recent discoveries expanded methylarginine reader biology beyond Tudor domains, including SART3 ( 39 ) and established MTA-cooperative PRMT5 inhibitors that exploit tumor metabolic state for selective targeting ( 40 , 41 ). Colored boxes denote conceptual categories: enzyme discovery, biochemistry, and biology (green); methylarginine readers and mechanisms (purple); and therapeutic development (orange). B , Biochemical reactions catalyzed by PRMTs. Type I, II, and III PRMTs catalyze processive methylation of arginine residues using S-adenosylmethionine (SAM) as a methyl donor, generating monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), or symmetric dimethylarginine (SDMA/Rme2s), with S-adenosylhomocysteine (SAH) as a byproduct. PRMT family members are classified by product specificity: Type I catalyzing MMA and ADMA (PRMT1, 2, 3, 4, 6, and 8), Type II catalyzing MMA and SDMA (PRMT5 and 9), and Type III only catalyzing MMA (PRMT7). " width="250" height="auto" />
    Fulllength Recombinant Human Prmt1, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/PRMT1+(NM_198319)+Human+Recombinant+Protein/pm42014716-654-17-30
    Average 94 stars, based on 1 article reviews
    fulllength recombinant human prmt1 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    Proteintech protein arginine methyltransferase 1
    Protein arginine methylation from biochemical discovery to therapeutic targeting. A , Timeline of key advances in arginine methylation biology, highlighting the progression from early biochemical identification of methylarginine and methyltransferase activity ( <xref ref-type=15 , 16 , 17 ) to molecular definition of protein arginine methyltransferases (PRMTs) ( 18 , 19 ). Early mechanistic studies demonstrated that arginine methylation regulates protein–protein interactions ( 20 ) and chromatin function through histone methylation by CARM1/PRMT4, PRMT1, and PRMT5 ( 21 , 22 , 23 ), while PRMT7 is unique in only catalyzing monomethylation ( 24 , 25 ). Tool development of specific antibodies ( 26 , 27 ) and inhibitors helped advance the field. The identification of methylarginine reader proteins, including SMN and TDRD3, and the structural definition of Tudor domain recognition established principles of methylarginine-dependent signaling ( 28 , 29 , 30 , 31 , 32 , 33 ). Translational advances include the development of selective PRMT5 inhibitors ( 34 , 35 ) and the discovery that MTAP loss leads to accumulation of methylthioadenosine (MTA), creating a synthetic lethal vulnerability to PRMT5 inhibition ( 36 , 37 , 38 ). More recent discoveries expanded methylarginine reader biology beyond Tudor domains, including SART3 ( 39 ) and established MTA-cooperative PRMT5 inhibitors that exploit tumor metabolic state for selective targeting ( 40 , 41 ). Colored boxes denote conceptual categories: enzyme discovery, biochemistry, and biology (green); methylarginine readers and mechanisms (purple); and therapeutic development (orange). B , Biochemical reactions catalyzed by PRMTs. Type I, II, and III PRMTs catalyze processive methylation of arginine residues using S-adenosylmethionine (SAM) as a methyl donor, generating monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), or symmetric dimethylarginine (SDMA/Rme2s), with S-adenosylhomocysteine (SAH) as a byproduct. PRMT family members are classified by product specificity: Type I catalyzing MMA and ADMA (PRMT1, 2, 3, 4, 6, and 8), Type II catalyzing MMA and SDMA (PRMT5 and 9), and Type III only catalyzing MMA (PRMT7). " width="250" height="auto" />
    Protein Arginine Methyltransferase 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/PRMT1+Antibody/pm41871629-63-0-41
    Average 93 stars, based on 1 article reviews
    protein arginine methyltransferase 1 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    95
    MedChemExpress prmt1 inhibitor
    Protein arginine methylation from biochemical discovery to therapeutic targeting. A , Timeline of key advances in arginine methylation biology, highlighting the progression from early biochemical identification of methylarginine and methyltransferase activity ( <xref ref-type=15 , 16 , 17 ) to molecular definition of protein arginine methyltransferases (PRMTs) ( 18 , 19 ). Early mechanistic studies demonstrated that arginine methylation regulates protein–protein interactions ( 20 ) and chromatin function through histone methylation by CARM1/PRMT4, PRMT1, and PRMT5 ( 21 , 22 , 23 ), while PRMT7 is unique in only catalyzing monomethylation ( 24 , 25 ). Tool development of specific antibodies ( 26 , 27 ) and inhibitors helped advance the field. The identification of methylarginine reader proteins, including SMN and TDRD3, and the structural definition of Tudor domain recognition established principles of methylarginine-dependent signaling ( 28 , 29 , 30 , 31 , 32 , 33 ). Translational advances include the development of selective PRMT5 inhibitors ( 34 , 35 ) and the discovery that MTAP loss leads to accumulation of methylthioadenosine (MTA), creating a synthetic lethal vulnerability to PRMT5 inhibition ( 36 , 37 , 38 ). More recent discoveries expanded methylarginine reader biology beyond Tudor domains, including SART3 ( 39 ) and established MTA-cooperative PRMT5 inhibitors that exploit tumor metabolic state for selective targeting ( 40 , 41 ). Colored boxes denote conceptual categories: enzyme discovery, biochemistry, and biology (green); methylarginine readers and mechanisms (purple); and therapeutic development (orange). B , Biochemical reactions catalyzed by PRMTs. Type I, II, and III PRMTs catalyze processive methylation of arginine residues using S-adenosylmethionine (SAM) as a methyl donor, generating monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), or symmetric dimethylarginine (SDMA/Rme2s), with S-adenosylhomocysteine (SAH) as a byproduct. PRMT family members are classified by product specificity: Type I catalyzing MMA and ADMA (PRMT1, 2, 3, 4, 6, and 8), Type II catalyzing MMA and SDMA (PRMT5 and 9), and Type III only catalyzing MMA (PRMT7). " width="250" height="auto" />
    Prmt1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prmt1/GSK3368715/pm40962202-174-1-7
    Average 95 stars, based on 1 article reviews
    prmt1 inhibitor - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Protein arginine methylation from biochemical discovery to therapeutic targeting. A , Timeline of key advances in arginine methylation biology, highlighting the progression from early biochemical identification of methylarginine and methyltransferase activity ( <xref ref-type=15 , 16 , 17 ) to molecular definition of protein arginine methyltransferases (PRMTs) ( 18 , 19 ). Early mechanistic studies demonstrated that arginine methylation regulates protein–protein interactions ( 20 ) and chromatin function through histone methylation by CARM1/PRMT4, PRMT1, and PRMT5 ( 21 , 22 , 23 ), while PRMT7 is unique in only catalyzing monomethylation ( 24 , 25 ). Tool development of specific antibodies ( 26 , 27 ) and inhibitors helped advance the field. The identification of methylarginine reader proteins, including SMN and TDRD3, and the structural definition of Tudor domain recognition established principles of methylarginine-dependent signaling ( 28 , 29 , 30 , 31 , 32 , 33 ). Translational advances include the development of selective PRMT5 inhibitors ( 34 , 35 ) and the discovery that MTAP loss leads to accumulation of methylthioadenosine (MTA), creating a synthetic lethal vulnerability to PRMT5 inhibition ( 36 , 37 , 38 ). More recent discoveries expanded methylarginine reader biology beyond Tudor domains, including SART3 ( 39 ) and established MTA-cooperative PRMT5 inhibitors that exploit tumor metabolic state for selective targeting ( 40 , 41 ). Colored boxes denote conceptual categories: enzyme discovery, biochemistry, and biology (green); methylarginine readers and mechanisms (purple); and therapeutic development (orange). B , Biochemical reactions catalyzed by PRMTs. Type I, II, and III PRMTs catalyze processive methylation of arginine residues using S-adenosylmethionine (SAM) as a methyl donor, generating monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), or symmetric dimethylarginine (SDMA/Rme2s), with S-adenosylhomocysteine (SAH) as a byproduct. PRMT family members are classified by product specificity: Type I catalyzing MMA and ADMA (PRMT1, 2, 3, 4, 6, and 8), Type II catalyzing MMA and SDMA (PRMT5 and 9), and Type III only catalyzing MMA (PRMT7). " width="100%" height="100%">

    Journal: The Journal of Biological Chemistry

    Article Title: Meeting report on FASEB protein arginine methylation: mechanism to therapeutics

    doi: 10.1016/j.jbc.2026.111448

    Figure Lengend Snippet: Protein arginine methylation from biochemical discovery to therapeutic targeting. A , Timeline of key advances in arginine methylation biology, highlighting the progression from early biochemical identification of methylarginine and methyltransferase activity ( 15 , 16 , 17 ) to molecular definition of protein arginine methyltransferases (PRMTs) ( 18 , 19 ). Early mechanistic studies demonstrated that arginine methylation regulates protein–protein interactions ( 20 ) and chromatin function through histone methylation by CARM1/PRMT4, PRMT1, and PRMT5 ( 21 , 22 , 23 ), while PRMT7 is unique in only catalyzing monomethylation ( 24 , 25 ). Tool development of specific antibodies ( 26 , 27 ) and inhibitors helped advance the field. The identification of methylarginine reader proteins, including SMN and TDRD3, and the structural definition of Tudor domain recognition established principles of methylarginine-dependent signaling ( 28 , 29 , 30 , 31 , 32 , 33 ). Translational advances include the development of selective PRMT5 inhibitors ( 34 , 35 ) and the discovery that MTAP loss leads to accumulation of methylthioadenosine (MTA), creating a synthetic lethal vulnerability to PRMT5 inhibition ( 36 , 37 , 38 ). More recent discoveries expanded methylarginine reader biology beyond Tudor domains, including SART3 ( 39 ) and established MTA-cooperative PRMT5 inhibitors that exploit tumor metabolic state for selective targeting ( 40 , 41 ). Colored boxes denote conceptual categories: enzyme discovery, biochemistry, and biology (green); methylarginine readers and mechanisms (purple); and therapeutic development (orange). B , Biochemical reactions catalyzed by PRMTs. Type I, II, and III PRMTs catalyze processive methylation of arginine residues using S-adenosylmethionine (SAM) as a methyl donor, generating monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), or symmetric dimethylarginine (SDMA/Rme2s), with S-adenosylhomocysteine (SAH) as a byproduct. PRMT family members are classified by product specificity: Type I catalyzing MMA and ADMA (PRMT1, 2, 3, 4, 6, and 8), Type II catalyzing MMA and SDMA (PRMT5 and 9), and Type III only catalyzing MMA (PRMT7).

    Article Snippet: In addition, Misuzu Hashimoto linked PRMT1 to CNS development and presented a model in which PRMT1 coordinates cell-type specific pathways critical for brain maturation.

    Techniques: Methylation, Activity Assay, Protein-Protein interactions, Inhibition